The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Selecting patients with AML for transplant: key considerations & the role of enhanced MRD monitoring
Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, comments on the current approach to determining which patients with acute myeloid leukemia (AML) should undergo transplantation. Dr Cluzeau notes that while patients with adverse risk typically receive transplants, the decision for those with intermediate risk is less clear, with ongoing research investigating the role of minimal residual disease (MRD) status in guiding treatment choices. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
